Terms: = Ovarian cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Diagnosis
18 results:
1. Circulating Biomarkers of Inflammation and ovarian cancer Risk in the Nurses' Health Studies.
Peres LC; Townsend MK; Birmann BM; Conejo-Garcia JR; Kim Y; Kubzansky LD; Magpantay LI; Martinez-Maza O; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):710-718. PubMed ID: 33563649
[TBL] [Abstract] [Full Text] [Related]
2. IL6, IL8, and IL10 in the distinction of malignant ovarian neoplasms and endometriomas.
Crispim PCA; Jammal MP; Antão PKA; Micheli DC; Tavares-Murta BM; Murta EFC; Nomelini RS
Am J Reprod Immunol; 2020 Dec; 84(6):e13309. PubMed ID: 32698242
[TBL] [Abstract] [Full Text] [Related]
3. Cytokines in peritoneal fluid of ovarian neoplasms.
de Lima CA; Silva Rodrigues IS; Martins-Filho A; Côbo Micheli D; Martins Tavares-Murta B; Candido Murta EF; Simões Nomelini R
J Obstet Gynaecol; 2020 Apr; 40(3):401-405. PubMed ID: 31476946
[TBL] [Abstract] [Full Text] [Related]
4. Stromal il2 is related to the neutrophil/lymphocyte ratio in epithelial ovarian cancer.
Santos TD; Jammal MP; Silveira TP; Murta EFC; Nomelini RS
Pathologica; 2019 Jun; 111(2):62-66. PubMed ID: 31388197
[TBL] [Abstract] [Full Text] [Related]
5. ΔNp73 status in peritoneal and ovarian dissemination of appendicular adenocarcinoids (goblet cells).
Prieto-Nieto MI; Pastor D; Rodríguez-Cobos J; Pérez JP; Méndez C; Palacios E; Arranz-Alvarez M; Santos-López J; Cano-Vega M; Viñal D; Rodríguez N; Domínguez G
Clin Transl Oncol; 2019 Oct; 21(10):1432-1439. PubMed ID: 31025168
[TBL] [Abstract] [Full Text] [Related]
6. Combined Immunotherapy (OK-432, il-2) With Chemotherapy Decrease the Recurrence Rate in Advanced ovarian cancer.
Wang YL; Peng HH; Su SY; Lin CT
Reprod Sci; 2019 Feb; 26(2):244-249. PubMed ID: 29658435
[TBL] [Abstract] [Full Text] [Related]
7. Role of Intracystic Cytokines and Nitric Oxide in ovarian Neoplasms.
Martins-Filho A; Jammal MP; Micheli DC; Tavares-Murta BM; Etchebehere RM; Murta EFC; Nomelini RS
Scand J Immunol; 2017 Dec; 86(6):462-470. PubMed ID: 28960399
[TBL] [Abstract] [Full Text] [Related]
8. Serum IL-6 and IL-8 Correlate with Prognostic Factors in ovarian cancer.
Sanguinete MMM; Oliveira PH; Martins-Filho A; Micheli DC; Tavares-Murta BM; Murta EFC; Nomelini RS
Immunol Invest; 2017 Oct; 46(7):677-688. PubMed ID: 28872976
[TBL] [Abstract] [Full Text] [Related]
9. Serum expression level of cytokine and chemokine correlates with progression of human ovarian cancer.
Luo JH; Zhang CY; Lu CY; Guo GH; Tian YP; Li YL
Eur J Gynaecol Oncol; 2017; 38(1):33-39. PubMed ID: 29767861
[TBL] [Abstract] [Full Text] [Related]
10. Effects of the balance between type 1 and type 2 T helper cells on ovarian cancer.
Hao CJ; Li J; Liu P; Li XL; Hu YQ; Sun JC; Wei Y
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323126
[TBL] [Abstract] [Full Text] [Related]
11. CD25 identifies a subset of CD4⁺FoxP3⁻ TIL that are exhausted yet prognostically favorable in human ovarian cancer.
deLeeuw RJ; Kroeger DR; Kost SE; Chang PP; Webb JR; Nelson BH
Cancer Immunol Res; 2015 Mar; 3(3):245-53. PubMed ID: 25480168
[TBL] [Abstract] [Full Text] [Related]
12. Correlation of cytokines and inducible nitric oxide synthase expression with prognostic factors in ovarian cancer.
Martins Filho A; Jammal MP; Côbo Ede C; Silveira TP; Adad SJ; Murta EF; Nomelini RS
Immunol Lett; 2014; 158(1-2):195-9. PubMed ID: 24447864
[TBL] [Abstract] [Full Text] [Related]
13. Plasma endothelial protein C receptor influences innate immune response in ovarian cancer by decreasing the population of natural killer and TH17 helper cells.
Azzazene D; Al Thawadi H; Al Farsi H; Besbes S; Geyl C; Mirshahi S; Pardo J; Faussat AM; Jeannette S; Therwath A; Pujade-Lauraine E; Mirshahi M
Int J Oncol; 2013 Oct; 43(4):1011-8. PubMed ID: 23877403
[TBL] [Abstract] [Full Text] [Related]
14. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
Nowak M; Glowacka E; Szpakowski M; Szyllo K; Malinowski A; Kulig A; Tchorzewski H; Wilczynski J
Neuro Endocrinol Lett; 2010; 31(3):375-83. PubMed ID: 20588232
[TBL] [Abstract] [Full Text] [Related]
15. Chronotherapy of ovarian cancer: effect on blood variables and serum cytokines. A case report.
Kanabrocki EL; Hermida RC; Haseman MB; Bettis K; Young RM; Mathew JP; Potkul R; Hrushesky WJ
Clin Ter; 2006; 157(4):349-54. PubMed ID: 17051973
[TBL] [Abstract] [Full Text] [Related]
16. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis.
Meager A; Wadhwa M; Dilger P; Bird C; Thorpe R; Newsom-Davis J; Willcox N
Clin Exp Immunol; 2003 Apr; 132(1):128-36. PubMed ID: 12653847
[TBL] [Abstract] [Full Text] [Related]
17. Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors.
Punnonen R; Teisala K; Kuoppala T; Bennett B; Punnonen J
Cancer; 1998 Aug; 83(4):788-96. PubMed ID: 9708947
[TBL] [Abstract] [Full Text] [Related]
18. Molecular aspects of breast and ovarian cancer.
Giannios J; Ioannidou-Mouzaka L
Eur J Gynaecol Oncol; 1997; 18(5):387-93. PubMed ID: 9378159
[TBL] [Abstract] [Full Text] [Related]
